Ranibizumab - 10mM histidine- histidine HCl buffer
CAS: 347396-82-1
Ref. 3D-BR171775
| 1mg | 457.00 € | ||
| 2mg | 638.00 € | ||
| 5mg | 866.00 € | ||
| 10mg | 1,221.00 € | ||
| 25mg | 2,274.00 € |
Product Information
- Lucentis
Ranibizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and blocks its action. It is used in the treatment of age-related macular degeneration and other diseases characterized by neovascularization, such as diabetic retinopathy and retinopathy of prematurity. Intravitreal ranibizumab injections have been shown to be effective for neovascular age-related macular degeneration, with a reduction in choroidal neovascularization and visual acuity improvement demonstrated in clinical trials. This drug has also been shown to reduce the incidence of new lesions in the retina and choroid, as well as to reduce or delay the development of new vessels. Ranibizumab is administered by intravitreal injection, which means it is injected into the vitreous humor inside the eye. The medication can be given alone or with bevacizumab (another VEG
Chemical properties
Technical inquiry about: 3D-BR171775 Ranibizumab - 10mM histidine- histidine HCl buffer
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
